• Biodesix flagged new real-world evidence on integrating Nodify Lung blood testing into routine pulmonary nodule care, slated for presentation at CHEST 2026.
• Analyses from the CLARIFY study of more than 2,000 tested patients point to added clinical value from sequencing biomarkers with PET imaging.
• Additional presentations indicate the testing can influence care decisions, improve follow-up adherence, and reduce reliance on more invasive diagnostics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodesix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610130600PRIMZONEFULLFEED9844274) on October 13, 2026, and is solely responsible for the information contained therein.